Well, it's time for this weekend's Appointed News quiz. I'm excited, as always, to see how I fare. I know you're excited as well.Let's go. Lisa Mateo has the categories. I won the one yesterday.I feel like this one is going to go your way. That's the unofficial point of this quiz. The quasi quasi appointed.It's why I didn't invest so much into it. Huh. Yeah, that's. That's the reason.All right. Listen, listen. What charter do you have for us today.Okay, so for those of you playing at home, maybe you're not ...

Bloomberg News has been named a finalist for the 2026 Pulitzer Prize for Explanatory Reporting for Cancer Capitalism series, investigating drug companies and health providers’ profits. Read the stories https://t.co/J2TUrbX75G https://t.co/ByHUzYdEBo ...

Switzerland’s Sandoz sees Canada and Brazil markets as testing grounds before semaglutide goes off patent in Europe and the U.S. in the 2030s. https://t.co/9nEfnPUxlD ...

Novo Nordisk saw a 40% surge in sales of its diabetes and weight-loss drugs in India last month https://t.co/18aNVE0tWf ...

Gilead said it now expects to book a loss in 2026 on $11.5 billion in charges after deals to acquire a string of companies making experimental cancer and autoimmune disease drugs https://t.co/VqTjk0MPkh ...

Today in Bloomberg Deals: South Korea is drawing in beauty deals, plus Li Ka-shing eyes more telco sales and Italian drugmaker Angelini Pharma has agreed to buy Catalyst Pharmaceuticals for $4.1 billion. https://t.co/IfrokEf7vW ...

Eli Lilly’s blockbuster diabetes drug Mounjaro has surpassed Merck’s cancer therapy Keytruda as the world’s best-selling medication https://t.co/dYIeDbXsBz ...

Eli Lilly is spending another $4.5 billion on its manufacturing plants in Indiana as the pharmaceutical company shores up its domestic supply chain. https://t.co/0Kpx54TUjD ...

So, Albert, thank you so much for joining us on this very special day for you at Pfizer. You had your first quarter results out, which were strong and beat estimates. As you look at those results.Why do you think you beat the estimates and what does it tell you about the rest of the year. Well, it's about execution. We were very focused and our commercial investing, which is basically the reflection of these commercial results, is one of a kind.They are very, very good. They understand the customer. They un ...

We were reviewing with our board uh the first molecule that we were able to completely design through AI just two weeks ago and uh 3 months ago we wouldn't be able to do it and 3 months later we have already a molecule already designed right in the face but also I want to say that when it speaks about AI there are two different uh areas one it is what technology can do now and cannot do everything But clearly can do much more than we are using to. And the bottleneck for something like that is not technologi ...